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Abstract
Background Risk minimization measures (RMM) were
implemented from February 2011 in the European Union to
address risks of superinfection, off-label use and lack of
efficacy associated with tigecycline. The objective of this
study was to evaluate RMM effectiveness by describing
prescription patterns among adults and children treated
with any dose of tigecycline for any indication pre- and
post-RMM implementation; incidence proportions of
superinfection and lack of efficacy among adults treated
with approved doses of tigecycline for complicated intra-
abdominal infection and complicated skin and soft tissue
infection were also evaluated.
Methods This was an observational, retrospective chart-
abstraction study, including charts from 777 patients (399
pre-RMM, 378 post-RMM) at 13 sites across Austria,
Germany, Italy, Greece and the United Kingdom (UK).
Potential superinfection and lack of efficacy cases among
those using tigecycline for on-label indication, age, dose,
and duration were adjudicated. The distribution of
indications for tigecycline was analyzed overall (i.e.
across both study periods) and stratified by study period.
Numbers and incidence proportions of superinfection and
lack of efficacy cases (potential and adjudicated) were
calculated overall and by study period.
Results Off-label use (indication or age) decreased from
54.2% [95% confidence interval (95% CI): 49.0, 59.3%]
pre-RMM to 35.7% (95% CI 30.4, 41.2%) post-RMM.
Overall, 45.7% (95% CI 41.9, 49.5%) of patients were
prescribed tigecycline off-label; the most commonly
reported off-label indications were characterized as
‘‘other’’ (25.5%), hospital acquired pneumonia (8.2%),
other pneumonia (6.3%), bacteremia (5.2%) and diabetic
foot infection (1.5%). Across study periods, incidence
proportions of definite or probable superinfection and
lack of efficacy in adults treated for approved indica-
tions, authorized treatment doses and duration were
4.5% (95% CI 2.1, 8.4%) and 5.5% (95% CI 2.8, 9.7%),
respectively.
Conclusions Off-label use of tigecycline decreased fol-
lowing RMM implementation. Overall incidence propor-
tions of definite or probable superinfection and lack of
efficacy were low. EU PAS register number: EUPAS3674
Key Points
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1 Introduction
Tigecycline is an intravenously administered broad-spec-
trum glycylcycline antibiotic, indicated in both the USA
and the European Union (EU) for treatment of complicated
intra-abdominal infection (cIAI) and complicated skin and
soft tissue infection (cSSTI) excluding diabetic foot
infection, and for community-acquired pneumonia in the
USA. It has broad-spectrum coverage, demonstrating
in vitro activity against both gram-positive and gram-neg-
ative pathogens [1]. Tigecycline is not affected by the two,
major tetracycline-resistance mechanisms as well as resis-
tance mechanisms such as beta-lactamases, target-site
modifications, macrolide efflux pumps or enzyme target
changes [2].
An increase in all-cause mortality has been observed
across Phase 3 and 4 clinical trials in tigecycline-treated
patients versus comparator-treated patients [3]. In all 13
controlled trials, death occurred in 4.0% (150/3788) of
patients receiving tigecycline and 3.0% (110/3646) of
patients receiving comparator drugs. In a pooled analysis of
these trials, the adjusted risk difference of all-cause mor-
tality was 0.6% [95% confidence interval (CI) 0.1, 1.2]
between tigecycline and comparator-treated patients [3].
The cause of the imbalance has not been established. One
independent meta-analysis of clinical trial data suggested
decreased clinical and microbiological efficacy of tigecy-
cline combined with higher rates of superinfections as
explanations [4], while others [5, 6] were not able to
identify any significant differences in efficacy or microbi-
ologic eradication to account for the results.
In order to reduce off-label prescribing of tigecycline,
and raise awareness of the risk of superinfection and lack
of efficacy, the marketing authorization holder (MAH)
agreed with the European Medicines Agency (EMA) to
develop and disseminate risk minimization measures
(RMMs) for tigecycline. RMMs are public health inter-
ventions intended to prevent the occurrence of adverse
drug reactions associated with exposure to a drug, or to
reduce its severity should the event occur [7]. The RMMs
for tigecycline included changes to the Summary of Pro-
duct Characteristics (SmPC) [8], a Direct to Healthcare
Professional Communication (DHPC), and a healthcare
provider educational program. Changes to the SmPC
highlighted approved uses of tigecycline in the EU, the
mortality imbalance observed in clinical trials and the risks
of superinfection and lack of efficacy, and emphasized that
tigecycline should be used only in situations where it is
known or suspected that other alternatives are not suitable.
The accompanying educational program was rolled out in
each country in the EU through pre-recorded webcast
sessions in local languages to which infectious disease
physicians, clinical microbiologists, intensive care physi-
cians, and surgeons were invited.
With the primary objective of assessing the effective-
ness of the modified SmPC and corresponding communi-
cation activities, and in accordance with EU legislation
requiring the evaluation of RMM effectiveness [9], the
MAH undertook a retrospective chart abstraction study in
the EU comparing prescription patterns among patients
treated with any dose of tigecycline for any indication (on-
or off-label), prior to and following implementation of the
RMM in February 2011. The study also evaluated the
incidence of adjudicated superinfection and lack of efficacy
among adult patients treated with tigecycline for the
approved duration of time and dosage for cIAI and cSSTI,
overall (i.e. across both study periods) and in each study
period separately.
2 Methods
A retrospective chart abstraction study was the optimal
design for this real-world evaluation of the effectiveness of
mandatory RMMs. Where the value of RMMs is deemed
clear, it is not ethical to withhold the RMM from a control
group [10]. Accordingly, the tigecycline RMMs were not
implemented using a phased approach: DHPCs were dis-
seminated to all countries inMarch 2011,while invitations to
participate in the educational program were issued in June
2011. It was therefore not possible to compare in parallel
sites or regions exposed to the RMM to control sites or
regions unexposed to the RMM. A chart abstraction design
was selected due to lack of electronic healthcare databases
with available inpatient prescription data in European
countries with high tigecycline prescription volume.
A total of 127 healthcare professionals (HCPs) at 121
hospitals and medical centers in Austria, Greece, Germany,
Italy, the United Kingdon (UK) and Spain were contacted
and asked to complete a site qualification questionnaire if
they were interested in participating in the study. The
questionnaire included questions about the number of
patients administered tigecycline during the two time-pe-
riods of interest (pre- and post-RMM implementation), and
the availability of human resources at the hospital or ward
for conducting such a study. Thirty-five HCPs responded to
the questionnaire. Twenty-two sites were initially selected,
of which 13 were ultimately included. For most of the sites
selected but not included, failure to initiate was due to
inability to meet study timelines. The two sites selected in
Spain were excluded because informed consent is required
from deceased and living patients in Spain, and including
only consenting patients would likely bias study results.
Similarly, since informed consent is required in Italy from
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all living patients, data from the three Italian sites were
included in sensitivity analyses only. All of the sites
included were academic centers.
Independent ethics committee (IEC) and/or institutional
review board (IRB) approval was obtained for each partic-
ipating site. In Austria, IEC approval was obtained from the
Ethics Committee of the Medical University of Vienna
(Ethik-Kommission der Medizinschen Universita¨t Wien und
des Allgemeinen Krankenhauses der Stadt Wien—AKH). In
Germany, approval was obtained from the Ethics Committee
of the University of Freiburg (Ethik-Kommission der
Universita¨t Freiburg) and the Ethics Committee of the
Charite´ Medical School Berlin Ethikkommission der Char-
ite´—Universita¨tsmedizin Berlin. In Greece, approval was
obtained from the Scientific Committees of Attikon Hospital
and the General Hospital of Athens Georgios Gennimatas. In
Italy, approvals were obtained from the Central Ethics
Committee of the University Hospital of Bologna (Comitato
Etico Indipendente dell ‘Azienda Ospedaliero-Universitaria
di Bologna Policlinico S.Orsola-Malpighi), the Ethics
Committee of the University Hospital of Verona (Comitato
Etico Indipendente dell ‘Azienda Ospedaliera Universitaria
Integrate Verona), and the Ethics Committee of the
University Hospital of Udine (Comitato Etico Indipendente
dell ‘Azienda Ospedaliera Universitaria di Udine). Finally,
approval in the UK was obtained from the NRES Committee
Yorkshire & The Humber-Leeds West.
All patients treated with at least one dose of tigecycline
for any indication within selected hospitals or wards
between 01 February 2010 and 01 February 2011 (pre-RMM
implementation period) and between 01 February 2012 and
01 February 2013 (post-RMM implementation period) were
retrospectively identified through review of electronic
medication databases or paper registries as eligible for
inclusion. Treatment with tigecycline during either of the
two study periods was the only inclusion criterion for the
study; there were no exclusion criteria. Eligible patients
either commenced or completed treatment with tigecycline
within the above-specified periods. Trained nurses or
physicians were instructed to abstract patient charts and
record data onto an electronic case report form in a random
order to avoid introduction of bias. Data were ‘‘key-coded’’
in order to preserve patient anonymity: only the site inves-
tigator was able to link the patient identification number to
any personally identifying information. Medical record data
prepared as part of the adjudication package were anon-
ymized prior to leaving the study site.
For the primary objective of assessing prescription patterns,
and particularly, the proportion of on-label use, among patients
treated with tigecycline prior to and following implementation
of the RMM in February 2011, on-label use was defined as use
for an on-label indication and in patients aged C18 years.
Potential cases of superinfection and lack of efficacy were
adjudicated for subjects with a narrower definition of on-label
use, namely, dosing regimens consistent with tigecycline
approved labeling (i.e. 100 mg loading dose; 25 or 50 mgBID
maintenance dosing), age C18 years and duration of tigecy-
cline treatment C48 h. Consideration of appropriate dosage
and duration of treatment were deemed necessary for the
accurate evaluation of efficacy and superinfection.
Potential superinfection cases were those where patient
charts revealed emergence of a new infection (evidence of
clinical diagnosis or microbiological results) not present at
baseline[2 days following initiation of tigecycline therapy.
New infection included either a new isolate at the site of the
primary infection or the development of an infection distant to
the site of primary infection. Potential lack of efficacy cases,
were those where additional intervention and/or antibiotic
therapy was provided in the absence of clinical improvement
to treat the infection, or death due to the infection occurred
[2 days following initiation of tigecycline therapy.
Two external adjudicators reviewed all relevant medical
record data from potential superinfection and lack of effi-
cacy cases (among on-label users) to classify potential
cases as either definite-, probable- or non-cases, or as
having insufficient information for adjudication; where
there was lack of consensus, a third adjudicator served as
tie-breaker. Classification of definite superinfection
required clinically significant positive culture of microor-
ganism[48 h after tigecycline therapy initiation in addi-
tion to clinical signs and symptoms of infection. If the
culture was from the same site, the microorganism was
required to be different than that isolated within the first
48 h, and if the culture was from a different site, the
microorganism could be any clinically significant
microorganism. Cases with inadequate surgical control
were not considered to be definite superinfection. Probable
superinfections met the criteria above but lacked culture
evidence for definite superinfection, while non-cases
lacked clinical signs or symptoms of superinfection.
Classification of definite lack of efficacy required a
clinically significant positive culture of a tigecycline-sus-
ceptible organism both before and after[48 h of tigecycline
therapy in addition to information on progression of infec-
tion (absence of clinical improvement); breakthrough
infections with this level of evidence were considered defi-
nite cases of lack of efficacy. In the case of death, the event
needed to be due to infection treated with tigecycline to be
considered a definite case of lack of efficacy. Cases with
inadequate surgical control were not considered definite lack
of efficacy. Probable lack of efficacy was defined as above,
but lacked culture evidence, and a non-case exhibited clin-
ical improvement after tigecycline therapy or a clinically
significant positive culture of an organism not susceptible to
tigecycline at baseline, or in the case of death, death not due
to the infection treated with tigecycline.
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2.1 Statistical Analysis
Characteristics of the sample including demographics,
comorbidities and disposition at discharge are summarized
with counts and percentages. Frequencies of indications for
which tigecycline was prescribed and the proportion of
these characterized as off-label use were calculated overall
(irrespective of study period) and for the periods before and
after RMM implementation. Counts and incidence pro-
portions of superinfection and lack of efficacy were simi-
larly calculated overall and pre- and post-RMM
implementation, for potential cases as well as adjudicated
cases. Reasons for adjudication as ‘‘non-cases’’ are also
summarized with counts and percentages.
An exploratory logistic regression analysis was con-
ducted to evaluate factors associated with off-label use (off-
label indication and pediatric use) throughout the entire
study period. The analysis was performed using backward
elimination and a p value criterion of 0.05. Covariates
included study period (pre-RMM or post-RMM), age (\65
or C65 years), gender, previous antibiotic therapy (yes vs.
no), country, previous surgical procedures (yes vs. no), and
number of co-morbidities (0, 1–3, C4).
3 Results
3.1 Patient and Site Characteristics
The primary analyses excluded the 90 patients enrolled in
three Italian sites for a total patient number of 687;
sensitivity analyses were conducted using all 777 patients.
The distribution of patients by country, site, and study
period is shown in Table 1.
Patient characteristics by indication and study period are
shown in Table 2. Irrespective of study period or indica-
tion, 52% of the study participants were male and mean age
on admission was 61.4 years (SD 16.40). Patients treated
with tigecycline before the RMM (for any indication) were
slightly older compared with those treated after the RMM
(mean 63.2, SD 15.98 vs. mean 59.2, SD 16.66).
At admission, over one-third of patients (36.7%) had
one or more forms of cardiovascular or cerebrovascular
disease. Almost one-third of patients (30.3%) had a history
of malignancy, and an immunocompromised state was
reported for 19.9%. Diabetes with (7.4%) or without
(17.6%) end-organ damage and moderate/severe renal
disease (24.6%) were also commonly reported. Liver dis-
ease was reported in 18.6% of patients, with most cases
characterized as moderate/severe. While inconsistently
recorded in patient charts, where recorded, 83.8% of
patients had baseline APACHE II scores C15 at baseline.
The burden of co-morbidities as assessed by the pres-
ence of relevant medical history appeared to be higher for
patients treated after the RMM compared to patients treated
before. For instance, higher proportions of patients treated
after the RMM had a history of malignancy (33.1 vs. 27.9%
pre-RMM), were in an immunocompromised state (21.7 vs.
18.5% pre-RMM), and had liver disease (22.9 vs. 15.0%
pre-RMM) or moderate/severe renal disease (28.0 vs.
21.7% pre-RMM). A higher proportion of prior antibiotic
use was seen following the RMM compared to before (87.1
Table 1 Distribution of patients by country and site
Site number Country Type of site Site of patient recruitment Number of patients enrolled
Before RMM After RMM Overall sample
1016 Austria University Hospital as a whole 38 51 89
1020 Austria University Infectious disease ward/department 5 7 12
1023 UK University Hospital as a whole 167 67 234
1030 UK University Intensive care unit 2 8 10
1015 Germany University Hospital as a whole 62 36 98
1024 Germany University Intensive care unit 39 43 82
1027 Germany University General and transplant surgery 26 57 83
1001 Germany University Intensive care unit 19 33 52
1004 Greece University Internal medicine 1 0 1
1006 Greece Public Hospital as a whole 14 12 26
1002 Italy University Hospital as a whole 12 0 12
1017 Italy University Hospital as a whole 11 19 30
1018 Italy University Hospital as a whole 3 45 48
Total no. patients 399 378 777
Total no. patients excluding Italy 373 314 687
RMM risk minimization measures
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vs. 69.1%); the difference was particularly notable among
off-label users (94.3 vs. 61.1%).
Across both study periods, all-cause mortality (31.7%)
was higher among patients with cIAI and off-label indi-
cations (34.7 and 32.5%, respectively) than patients with
cSSTI (20.6%). The all-cause mortality rate was lower
before the RMM (28.2%) compared to after (36.0%).
While this trend was consistent across all indications (cIAI,
cSSTI, off-label), the increase was particularly notable in
the cIAI (30.2 vs. 38.7%) and off-label (27.7 vs. 42.0%)
population subgroups. All pediatric patients were dis-
charged alive (data not shown in Table).
3.2 Off-Label Use of Tigecycline
Overall, 45.7% of patients treated with tigecycline (95% CI
41.9, 49.5%) were treated for an off-label indication or
pediatric use (Table 3). Prior to RMM implementation,
54.2% of the indications were off-label or pediatric use
(95% CI 49.0, 59.3%) compared to 35.7% (95% CI 30.4,
41.2%) after RMM implementation. Sensitivity analyses
including data from Italy were consistent with these find-
ings. A decrease in off-label use post-RMM was seen
across all countries. The lowest proportion of overall off-
label use was observed in Italy (25.4%) and the highest was
observed in Austria (60.4%).
The most commonly reported off-label indications
were characterized as ‘‘other’’ (25.5%), hospital-acquired
pneumonia (8.2%), other pneumonia (6.3%), bacteremia
(5.2%) and diabetic foot infection (1.5%). Prior to
implementation of the RMM, 62.8% of those with off-
label indications were treated for ‘‘other’’ off-label
indications (i.e. off-label indications other than hospital
acquired pneumonia, other pneumonia, diabetic foot
Table 3 Indications for use and
off-label use, primary analysis
Pre-RMM
n (%)
Post-RMM
n (%)
Overall
n (%)
Indications for use among adult patients# n = 370 n = 309 n = 679
cIAI 129 (34.9) 142 (46.0) 271 (39.9)
cSSTI 42 (11.4) 60 (19.4) 102 (15.0)
Off-label indications 199 (53.8) 107 (34.6) 306 (45.1)
Hospital acquired pneumonia 31 (8.4) 25 (8.1) 56 (8.2)
Pneumonia (other) 23 (6.2) 20 (6.5) 43 (6.3)
Diabetic foot infection 7 (1.9) 3 (1.0) 10 (1.5)
Bacteremia 19 (5.1) 16 (5.2) 35 (5.2)
Other 125 (33.8) 48 (15.5) 173 (25.5)
Off-label use (indication and pediatric use*) in total and by country
Total n = 373 n = 314 n = 687
On-label use 171 (45.8) 202 (64.3) 373 (54.3)
Off-label use 202 (54.2) 112 (35.7) 314 (45.7)
Germany n = 146 n = 169 n = 315
On-label use 82 (56.2) 126 (74.6) 208 (66.0)
Off-label use 64 (43.8) 43 (25.4) 107 (34.0)
Austria n = 43 n = 58 n = 101
On-label use 15 (34.9) 25 (43.1) 40 (39.6)
Off-label use 28 (65.1) 33 (56.9) 61 (60.4)
Greece n = 15 n = 12 n = 27
On-label use 9 (60.0) 9 (75.0) 18 (66.7)
Off-label use 6 (40.0) 3 (25.0) 9 (33.3)
UK n = 169 n = 75 n = 244
On-label use 65 (38.5) 42 (56.0) 107 (43.9)
Off-label use 104 (61.5) 33 (44.0) 137 (56.1)
RMM risk minimization measures, cIAI complicated intra-abdominal infection, cSSTI complicated skin and
soft tissue infection
# One adult patient prescribed tigecycline for cIAI was excluded from these analyses due to an inappro-
priate dosing sequence
* The patient receiving an inappropriate dosing sequence is considered an off-label user (despite cIAI
indication and adult age)
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infection or bacteremia), versus 44.9% after implemen-
tation of the RMM.
In the exploratory logistic regression analysis performed
to evaluate factors associated with off-label use (Table 4),
treatment in the post-RMM period was associated with
significantly decreased odds of off-label use compared with
treatment in the pre-RMM period [adjusted odds ratio (OR)
0.66, 95% CI 0.46, 0.94]. Patients in Austria (OR 2.46,
95% CI 1.48, 4.11) and the UK (OR 1.59, 95% CI 1.04,
2.41) were significantly more likely to be treated off-label
compared with patients in Germany. No history of previous
surgical procedures was associated with increased likeli-
hood of off-label use (OR 4.52, 95% CI 3.10, 6.59). No
other variables reached statistical significance.
3.3 Superinfection
The overall incidence of definite and probable superinfec-
tion across approved indications, ages, doses and treatment
durations (n = 199) was 4.5% (95% CI 2.1, 8.4%), with
3.8% pre-RMM (95% CI 1.1, 9.5%) and 5.3% post-RMM
(95% CI 1.8, 12.0%) (Table 5). Sensitivity analyses
including data from Italy were consistent with the primary
analysis results.
Sixty potential superinfection cases were reported.
Potential superinfection was reported in 32.5 and 22.9%
of cIAI and cSSTI cases, respectively, in total (pre- and
post-RMM). Amongst the 49 cIAI potential superinfec-
tion cases, 6 (12.2%) were adjudicated as probable or
definite cases. Associated pathogens were Enteroccocus
spp. (n = 4), Klebsiella spp. (n = 3), Escherichia coli
(n = 2), Proteus spp. (n = 1) and Pseudomonas aerugi-
nosa (n = 1). For 4 cases, the information available was
considered insufficient for adjudication, and 39 were
determined not to be a superinfection. Amongst the 11
cSSTI potential superinfection cases, 3 (27.2%) were
adjudicated to be probable or definite cases. Associated
pathogens were one report each of Enteroccocus spp.,
Proteus spp., Enterobacter spp. and Citrobacter spp. For
two cases, the information available was considered
insufficient for adjudication, and six were determined not
to be a superinfection. For the cases that were determined
not to be a superinfection, reasons are detailed in
Table 5.
3.4 Lack of Efficacy
The overall incidence proportion of definite and probable
lack of efficacy among patients treated with tigecycline for
on-label indications, ages, doses and treatment durations
was 5.5% (95% CI 2.8, 9.7%), with 2.9% pre-RMM (95%
CI 0.6, 8.1%) and 8.5% after (95% CI 3.8, 16.1%)
(Table 6). Sensitivity analyses including data from the
Italian sites found similar results.
Among the 199 patients using tigecycline for approved
indications, ages, doses and treatment durations, 107
potential lack of efficacy cases were reported (54.3% of
cIAI cases and 52.1% of cSSTI cases). Amongst the 82
cIAI potential lack of efficacy cases, 8 (9.8%) were adju-
dicated as either probable or definite cases (6 probable, 2
definite). For 7 cIAI cases, the information available was
considered insufficient for adjudication, and 67 were
determined not to be lack of efficacy. Amongst the 25
cSSTI potential lack of efficacy cases, 3 cases (12.0%)
were adjudicated as probable cases and none were adju-
dicated as definite. For 3 cases, the information available
was considered insufficient for adjudication, and 19 were
determined not lack of efficacy. Reasons for which cases
Table 4 Predictors of off-label use (off-label indication and pediatric
use), primary analysis
Adjusted odds ratio (95% CI)*
Study period
Pre-RMM Reference
Post-RMM 0.657 (0.460, 0.938)
Age
\65 Reference
C65 1.094 (0.769, 1.556)
Gender
Male Reference
Female 0.834 (0.589, 1.180)
Previous antibiotic therapy
Yes Reference
No 0.837 (0.535, 1.310)
Country
Germany Reference
Austria 2.463 (1.476, 4.110)
Greece 0.452 (0.182, 1.123)
UK 1.585 (1.042, 2.413)
Number of co-morbidities
0 Reference
1–3 1.094 (0.681, 1.758)
4 or more 1.056 (0.512, 2.177)
Previous surgical procedures
Yes Reference
No 4.521 (3.101, 6.590)
The prescription of tigecycline for one patient was considered to be
off-label because of the dosing sequence, despite this patient being
prescribed tigecycline for cIAI and being over 18 years of age
RMM risk minimization measures, cIAI complicated intra-abdominal
infection, CI confidence interval
* P (y|x) = 1/(1 ? e-a-bx), where y = the probability of disease,
x = a given risk factor, and e is the exponential function. In the case
of multiple adjustments, bx is replaced by a linear term involving
factors representing each risk x (e.g. b1x1 ? b2x2, etc.). The reference
category is the level of the categorical variable against which other
levels of that variable are compared
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were determined not to indicate lack of efficacy are
detailed in Table 6.
4 Discussion
This observational study suggests an important role of
RMM in decreasing off-label use of tigecycline and reveals
low overall incidence proportions of definite and probable
superinfection and lack of efficacy in five European
countries.
Less than one-half of patients were administered tige-
cycline for an off-label indication. A 2012 systematic
review of off-label prescribing of antibiotics found off-
label prescribing of antibiotics to vary from 19 to 43% in
adult critical-care settings, with 31–78% of tigecycline
prescriptions for off-label uses [11]. Physicians may use
therapeutic agents for non-approved indications out of
medical necessity. For instance, tigecycline, as a broad-
spectrum antibiotic, is often used to treat multidrug-resis-
tant infections, sometimes for off-label indications, where
other antibiotics are unavailable/ineffective [12, 13], or
otherwise unsuitable. Physicians must understand the
proper on-label use of a product in order to make informed
decisions regarding when the product should and should
not be used.
Notably, off-label use of tigecycline decreased after
implementation of the RMM, and the post-RMM period
Table 5 Incidence of potential and adjudicated superinfection by approved indication* (primary analysis)
Pre-RMM (n = 105) Post-RMM (n = 94) All patients (n = 199)
cIAI
n (%)
cSSTI
n (%)
cIAI
n (%)
cSSTI
n (%)
cIAI
n (%)
cSSTI
n (%)
No. patients treated for approved indications 82 (78.1) 23 (21.9) 69 (73.4) 25 (26.6) 151 (75.9) 48 (24.1)
No. patients with potential superinfection 23 (28.0) 3 (13.0) 26 (37.7) 8 (32.0) 49 (32.5) 11 (22.9)
Adjudicated case status n = 23 n = 3 n = 26 n = 8 n = 49 n = 11
Definite 2 (8.7) 1 (33.3) 0 (0.0) 1 (12.5) 2 (4.1) 2 (18.2)
Probable 1 (4.3) 0 (0.0) 3 (11.5) 1 (12.5) 4 (8.2) 1 (9.1)
Not a case 17 (73.9) 1 (33.3) 22 (84.6) 5 (62.5) 39 (79.6) 6 (54.5)
Insufficient information 3 (13.0) 1 (33.3) 1 (3.8) 1 (12.5) 4 (8.2) 2 (18.2)
If status = ‘Not a case’ n = 17 n = 1 n = 22 n = 5 n = 39 n = 6
A. Lacking clinical signs and symptoms of superinfection 2 (11.8) 0 (0.0) 2 (9.1) 0 (0.0) 4 (10.3) 0 (0.0)
B. Same organism is cultured from the same site as initial infection 1 (5.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6) 0 (0.0)
C. Inadequate surgical control 1 (5.9) 0 (0.0) 4 (18.2) 0 (0.0) 5 (12.8) 0 (0.0)
Other reason (as combination of above)±
A and B 2 (11.8) 0 (0.0) 0 (0.0) 1 (20.0) 2 (5.1) 1 (16.7)
A and C 3 (17.6) 0 (0.0) 6 (27.3) 2 (40.0) 9 (23.1) 2 (33.3)
B and C 1 (5.9) 0 (0.0) 6 (27.3) 0 (0.0) 7 (17.9) 0 (0.0)
A, B and C 1 (5.9) 0 (0.0) 1 (4.5) 0 (0.0) 2 (5.1) 0 (0.0)
Other reasons (not included in above) 6 (35.3) 1 (100.0) 3 (13.6) 2 (40.0) 9 (23.1) 3 (50.0)
Pathogen associated with superinfection (definite and probable) **#^ n = 3 n = 1 n = 3 n = 2 n = 6 n = 3
Enterococcus spp. 3 (100.0) 0 (0.0) 1 (33.3) 1 (50.0) 4 (66.7) 1 (33.3)
E. coli 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 2 (33.3) 0 (0.0)
Proteus spp. 1 (33.3) 0 (0.0) 0 (0.0) 1 (50.0) 1 (16.7) 1 (33.3)
Klebsiella spp. 2 (66.7) 0 (0.0) 1 (33.3) 0 (0.0) 3 (50.0) 0 (0.0)
Enterobacter spp. 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.3)
Citrobacter spp. 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 1 (33.3)
P. aeruginosa 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 1 (16.7) 0 (0.0)
RMM risk minimization measures, cIAI complicated intra-abdominal infection, cSSTI complicated skin and soft tissue infection
* Among those with dosing regimens consistent with tigecycline approved labeling, age C18 years and duration of tigecycline treatment[48 h
** For definite and probable superinfection
# Percentages may not add to 100% as one superinfection case can be associated with multiple pathogens
^ Percentages use the sub-total of definite and probable superinfections as the denominator
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was found to be significantly protective of off-label use in
exploratory multivariate analyses (OR 0.66, 95% CI 0.46,
0.94). We explored whether unmeasured factors may have
influenced the relationship between the RMM and off-label
use. Sites were queried regarding the occurrence of any
event that could have affected prescribing of tigecycline
during the study periods. The reported circumstances (two
sites) did not provide support for a pattern of decreased off-
label use in the post-RMM period: one site reported an
increase in carbapenemase-producing Klebsiella pneumo-
niae in both study periods, resulting in several cases where
colistin and tigecycline were the only active antibiotics; the
other reported an increase in tigecycline use across both
study periods due to supply problems with aztreonam (pre-
RMM) and an outbreak of vancomycin-resistant entero-
coccus (post-RMM).
Incidence proportions of definite or probable superin-
fection observed among on-label users of tigecycline in the
pre-RMM and post-RMM periods were low (3.8 and 5.3%,
respectively) compared to published estimates. Interpreta-
tion of differences in definite and probable superinfection
between pre- and post-RMM periods within our study is
difficult due to wide confidence intervals around these
estimates. With regard to overall proportions of superin-
fection, in a single-site study of patients in Turkey,
superinfection (defined as the eradication of the microor-
ganism that was present at the beginning of the treatment
and the isolation of a new causative pathogen after C48 h
of treatment) was detected in 14.9% of the cSSTI and 7.5%
of cIAI patients [14]. Reasons for differences between rates
in that study and our own are unclear but may be related to
differences in adjudication criteria or underlying differ-
ences in the treated population.
Similar to superinfection, low incidence of definite or
probable lack of efficacy among on-label users was also
seen in both study periods (2.9 and 8.5% in the pre- and
post-RMM periods, respectively). As above, interpretation
of differences by study period is difficult due to wide
confidence intervals. Though our estimates may be unsta-
ble, lack of efficacy estimates irrespective of study period
among on-label users in our study appear somewhat lower
than those found in a multi-country European observational
Table 6 Incidence of potential and adjudicated lack of efficacy by approved indication* (primary analysis)
Pre-RMM(n = 105) Post-RMM(n = 94) All patients(n = 199)
cIAI
n (%)
cSSTI
n (%)
cIAI
n (%)
cSSTI
n (%)
cIAI
n (%)
cSSTI
n (%)
No. patients treated for approved indications 82 (78.1) 23 (21.9) 69 (73.4) 25 (26.6) 151 (75.9) 48 (24.1)
No. patients with potential lack of efficacy 38 (46.3) 9 (39.1) 44 (63.8) 16 (64.0) 82 (54.3) 25 (52.1)
Adjudicated case status n = 38 n = 9 n = 44 n = 16 n = 82 n = 25
Definite 1 (2.6) 0 (0.0) 1 (2.3) 0 (0.0) 2 (2.4) 0 (0.0)
Probable 0 (0.0) 2 (22.2) 6 (13.6) 1 (6.3) 6 (7.3) 3 (12.0)
Not a case 31 (81.6) 6 (66.7) 36 (81.8) 13 (81.3) 67 (81.7) 19 (76.0)
Insufficient information 6 (15.8) 1 (11.1) 1 (2.3) 2 (12.5) 7 (8.5) 3 (12.0)
If status = ‘Not a case’ n = 31 n = 6 n = 36 N = 13 n = 67 n = 19
A. Evidence of clinical improvement after Tigecycline therapy 8 (25.8) 1 (16.7) 3 (8.3) 2 (15.4) 11 (16.4) 3 (15.8)
B. Clinically significant positive culture of an organism not
susceptible to tigecycline at baseline
1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0)
C. Death not due to the infection treated with Tigecycline 1 (3.2) 0 (0.0) 0 (0.0) 2 (15.4) 1 (1.5) 2 (10.5)
D. Inadequate surgical control 5 (16.1) 0 (0.0) 7 (19.4) 1 (7.7) 12 (17.9) 1 (5.3)
Other reasons (as combination of above)#
A and B 1 (3.2) 0 (0.0) 0 (0.0) 2 (15.4) 1 (1.5) 2 (10.5)
A and C 1 (3.2) 2 (33.3) 1 (2.8) 0 (0.0) 2 (3.0) 2 (10.5)
A and D 4 (12.9) 0 (0.0) 7 (19.4) 4 (30.8) 11 (16.4) 4 (21.1)
B and D 5 (16.1) 1 (16.7) 3 (8.3) 1 (7.7) 8 (11.9) 2 (10.5)
C and D 0 (0.0) 1 (16.7) 6 (16.7) 0 (0.0) 6 (9.0) 1 (5.3)
A and C and D 1 (3.2) 0 (0.0) 1 (2.8) 0 (0.0) 2 (3.0) 0 (0.0)
B and C and D 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 1 (1.5) 0 (0.0)
Other reasons (not included in above) 4 (12.9) 1 (16.7) 7 (19.4) 1 (7.7) 11 (16.4) 2 (10.5)
RMM, risk minimization measures, cIAI complicated intra-abdominal infection, cSSTI complicated skin and soft tissue infection
* Among those with dosing regimens consistent with tigecycline approved labeling, age greater than or equal to 18 years and duration of
tigecycline treatment[48 h
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study. Montravers and colleagues, in one publication based
on that study, found 11.7% definite non-response among
cSSTI patients [15], while Eckmann and colleagues
reported a non-response frequency of 14.2% among cIAI
patients in the same population as that reported on by
Montravers et al. [16]. Where differences in lack of effi-
cacy across patient populations exist, these could be due to
differences in patient illness severity or other factors (e.g.
timing of treatment) that lead to failure of anti-infective
drugs in general. Indeed, baseline APACHE II scores were
higher in our study: 83.8% in the present study versus
16.6% in the above-mentioned multi-country study had
scores[15 at baseline [17]. Thus, baseline disease severity
may be a contributing factor.
Overall, the mortality rate among tigecycline-treated
patients in this study was 31.7%. Patients treated for cIAIs
and off-label indications had higher mortality rates (34.7
and 32.5%, respectively) than patients with cSSTI (20.6%).
Notably, the mortality rate appeared to be higher after the
RMM, most notably in the cIAI and off-label population
subgroups. There were important differences noted in the
populations after the RMM compared with before the
RMM, which may have contributed to differences in
mortality. These include increased proportions of surgical
intervention and prior antibiotic use preceding tigecycline
use, an increased burden of comorbidities, and an increase
in the proportion of patients with resistant organisms after
the RMM relative to before the RMM, particularly among
cIAI and off-label indication patients. Indeed, it is likely
that the risk minimization measures (particularly SmPC
text stating that tigecycline should be used only in situa-
tions where it is known or suspected that other alternatives
are not suitable) influenced prescribers to channel tigecy-
cline to more severely ill patients (frequently those patients
who have failed other therapies, or have resistant organ-
isms not sensitive to other therapies).
This study has several strengths. It is a relatively rare
example of an RMM program evaluation employing a pre-
versus post-intervention comparison study design, relying
on site-level chart review data and including clinical end-
points as study outcomes [18]. The collection of site-level
data allowed linkage among inpatient diagnosis, procedure,
medication, and microbiology (when available) data for EU
patients, a linkage not accommodated by currently avail-
able databases in these countries. Adjudication of potential
cases of superinfection and lack of efficacy allowed for
objective assessments of these endpoints. Moreover, com-
pared with clinical trials, this study provides an estimate of
superinfection and lack of efficacy rates in a patient pop-
ulation with a greater number of comorbidities, higher
illness severity scores, and a higher proportion of resistant
organisms [19], more closely mirroring the population
using tigecycline in clinical practice.
This study also had some limitations. The ability to
directly attribute the change in off-label use to the RMM is
limited. While we evaluated the role of changes in
antimicrobial resistance and local circumstances, other
unmeasured factors independent of the RMM (e.g. a shift
in prescribing practices unrelated to the RMM or increased
availability of other treatments) may also have influenced
tigecycline prescribing. The study also did not examine the
role of exposure to individual components of the RMM on
study endpoints. It is not possible to determine to which (if
any) component of the RMM the treating physicians had
been exposed, or if tigecycline was prescribed only in a
situation where it was known or suspected that other
alternatives were not suitable. However, the increased
mortality in the post-RMM period suggests increased use
of tigecycline in patients who have failed other therapies,
or have resistant organisms not sensitive to other therapies,
consistent with the SmPC. In addition, lack of sufficient
data on microbiology and clinical assessments in the
medical record data made case classification difficult in
some cases.
Finally, the generalizability of study results is unknown.
Participating sites may not be comparable to those that did
not participate in the study. However, the geographical
distribution of the study still included four high-prescribing
tigecycline countries in the EU, and sensitivity analyses
including Italy exhibited results consistent with the primary
analyses. These five countries represented almost three-
quarters of tigecycline usage in the EU according to 2009
sales data. It should be noted, however, that the majority of
patients were enrolled by sites in Germany (315/687,
45.9%) and the UK (244/687, 35.5%), which may limit
somewhat the external validity of the results beyond these
two countries. Generalizability of the results to RMM
programs targeting drugs that have lower baseline levels of
off-label use is also unknown.
5 Conclusions
In conclusion, this study found a decreased proportion of
off-label use following the implementation of RMM, a
notable finding which must be interpreted in light of the
study limitations above. Importantly, the study also found
low proportions of definite and probable superinfection and
lack of efficacy among on-label users across both study
periods and in a real-life treatment setting, providing fur-
ther evidence that tigecycline may be an important alter-
native when other anti-infective agents are not suitable.
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